Immunocore

Immunocore, are a pioneering, commercial-stage T cell receptor biotechnology company working to develop and commercialise a new generation of transformative medicines to address unmet needs in cancer, infectious and autoimmune diseases. 

Their initial therapeutic focus is in oncology, where pivotal clinical trials are currently underway for lead program, tebentafusp (IMCgp100), as a potential treatment for metastatic uveal melanoma, a rare form of eye cancer.

They also have a robust pipeline of programs spanning a broad range of cancer indications, as well as infectious and autoimmune diseases. 

Regularly, the business acquires some of the most talented individuals across the global market to work in their offices within the UK on life transforming projects whilst remaining compliant with UK Immigration rules.

Migrate’s Involvement

We are assigned with the task to assist all sponsored employees, overseas and UK based, and ensure they are onboarded as efficiently as possible.

A smooth process allows the candidate to join the business with one less thing to worry about. With the current backlogs being experienced by UKVI, we work on tight deadlines and quickturnarounds for application submissions, especially since UKVI have resumed priority processing.\

As always, the business is keen to develop talent in the UK and one such case involved onboarding a new employee who was already in the UK working for another employer. 

The business was notified that the migrant’s visa was due to expire the following day.

Migrate UK was instructed and within 24 hours the application was submitted prior to visa expiry under priority processing and the visa was in hand within 3 weeks.

Results

The employee remained in the UK legally at all times andwas kept up to date on progress throughout.

Migrate UK handled the process with less than 24 hours’ notice and as efficiently as possible.

As a result, the applicant and his family remained in the UK, compliant with the immigration rules.